Organon & Co. Reports Q2 2026 Results; Furnishes Non‑GAAP Metrics

What Happened

• Organon & Co. announced it filed its Quarterly Report on Form 10‑Q with the SEC on July 31, 2026, reporting results for the quarter ended June 30, 2026.
• Because of the company’s pending merger with Sun Pharmaceutical Industries Limited, Organon has suspended its usual quarterly earnings press release and conference call. To continue providing investors helpful context, the company furnished supplemental non‑GAAP financial metrics for Q2 2026 in Exhibit 99.1 to the Form 8‑K.

Key Details

• Form 10‑Q for the quarter ended June 30, 2026 was filed with the SEC on July 31, 2026.
• The company suspended its customary earnings press release and earnings call due to the pending merger with Sun Pharmaceutical Industries Limited.
• Exhibit 99.1 to the 8‑K contains supplemental non‑GAAP financial metrics for Q2 2026; these are provided in addition to, and should be read with, Organon’s GAAP financial statements in the Form 10‑Q.
• The disclosure was made under Item 7.01 (Regulation FD Disclosure) and the supplemental information is furnished, not filed, with the SEC.

Why It Matters

• Investors get access to supplemental non‑GAAP metrics that Organon has historically provided with its quarterly results, even though the company is not issuing a standalone earnings release or hosting a call. These metrics may help interpret quarterly revenue and operating performance but are not a substitute for GAAP results.
• The pending merger with Sun Pharmaceutical is limiting the company’s usual investor communications; shareholders should review the Form 10‑Q and Exhibit 99.1 to see the company’s official GAAP results and the accompanying non‑GAAP metrics before making decisions.